Recombinant Human IL36RN Protein，His

IL36RN (Interleukin-36 Receptor Antagonist) is a critical component in the regulation of the immune system and has garnered increasing attention in recent years due to its role in various inflammatory diseases, particularly in skin disorders like psoriasis and other autoinflammatory conditions. IL36RN encodes a protein that acts as a natural antagonist to the interleukin-36 (IL-36) cytokines, which are important mediators of the inflammatory response. Mutations or deficiencies in IL36RN have been linked to severe forms of generalized pustular psoriasis (GPP), highlighting its significance in maintaining immune homeostasis. Research on recombinant IL36RN protein has focused on its therapeutic potential in modulating excessive inflammatory responses by blocking the action of IL-36 cytokines. This has led to the exploration of IL36RN as a candidate for targeted therapies in treating both chronic inflammatory diseases and acute flare-ups. Furthermore, understanding the structure and function of the IL36RN protein enables researchers to investigate its interactions with other components of the immune system, providing insights into the underlying mechanisms of inflammation and paving the way for innovative treatment strategies that could improve patient outcomes in autoinflammatory diseases. Thus, IL36RN recombinant protein research is critical not only for elucidating its biological functions but also for developing new therapeutic avenues for managing inflammation-driven diseases.